It is unclear whether non-invasive screening of asymptomatic diabetic patients for coronary artery disease (CAD) may improve cardiac outcomes. Thus, we performed a systematic literature review and meta-analysis of randomised controlled trials (RCT's) on this topic. We searched appropriate RCT's in five online databases (PubMed/MEDLINE, Cochrane Library, Embase, Scopus, and Web of Science) from January 2000 to November 2017 and in 41 recent reviews. Two investigators independently extracted and assessed study data using standardised forms. Additional unpublished data were obtained from trial authors. The primary endpoint 'any cardiac event' was a composite of cardiac death, non-fatal myocardial infarction (MI), unstable angina (UA), or heart failure (HF) hospitalisation. We performed a meta-analysis of relative risks (RRs) with 95% confidence intervals (CI) using the Mantel-Haenszel method. We included five RCT's with 3299 patients, of which 189 (5.7%) experienced any cardiac event on follow-up (weighted mean 4.1 years). Non-invasive CAD screening significantly reduced any cardiac event by 27% [RR 0.73 (95% CI 0.55-0.97), P = 0.028, number needed to screen 56]. This result was driven by important, albeit non-significant decreases in non-fatal MI [RR 0.65 (95% CI 0.41-1.02), P = 0.062] and HF hospitalisation [RR 0.61 (95% CI 0.33-1.10), P = 0.100]. Non-invasive CAD screening did not significantly affect cardiac death ), P = 0.77] and UA , P = 0.29]. Compared with the standard care, non-invasive CAD screening reduced cardiac events by 27% in asymptomatic diabetic patients, largely through reductions in non-fatal MIs, and HF hospitalisations. The present results justify larger, appropriately powered trials to potentially revisit current recommendations.
Introduction
Globally, an estimated 422 million people are living with diabetes mellitus, a number that has doubled over the past 20-30 years. 1 By 2045, the International Diabetes Federation expects a further increase to 629 million diabetic patients worldwide. 2 Diabetes mellitus confers a two-fold increased risk of coronary artery disease (CAD), 3 which is the major cause of mortality and morbidity in diabetic patients. [4] [5] [6] Unfortunately, in these patients, CAD may often be asymptomatic until the onset of myocardial infarction (MI) or sudden cardiac death. 4, 5, 7 Indeed, silent cardiac ischaemia can be detected on average in 26% of asymptomatic diabetic patents, exposing them to a 3.5-fold increased risk of cardiac events. 8 Hence, diabetes mellitus has been considered a CAD risk equivalent. 9 The current standards of care for asymptomatic diabetic patients are based on risk factor modification, lifestyle changes, and medical therapy. 6, 10 However, the high cardiovascular risk in these patients has also generated substantial interest in the early detection of silent CAD by screening tests. 5 In addition to exercise electrocardiogram test (EET), recent technological advances have produced a number of sophisticated imaging tools to assess non-invasively the presence and severity of CAD, including stress echocardiography (SE), stress radionuclide myocardial perfusion imaging (MPI), coronary artery calcium scoring (CACS), and computed tomography coronary angiography (CTCA). 11 Myocardial ischaemia, high CACS and significant coronary stenosis have all been associated with worse outcomes in non-diabetic 12, 13 and diabetic patients. 8, 11, 14, 15 However, whether pre-emptive coronary revascularization and intensification of medical therapy based on routine CAD screening may improve outcomes of asymptomatic diabetic patients is currently under debate. 16, 17 Experts favouring screening 5, 16 refer to the improvement of risk classification, 18 and the reduction of scintigraphic CAD progression with invasive treatment. 19 However, opponents advocate optimal medical treatment without screening because revascularization has not convincingly been demonstrated to reduce cardiovascular events in diabetic patients. 20, 21 Moreover, first exploratory randomised controlled trials (RCT's) failed to demonstrate any prognostic benefit of CAD screening. However, these trials may have suffered from under-sampling and potential statistical Type II error due to lower event rates than anticipated. 22, 23 We, therefore, sought to perform a systematic review and metaanalysis of published RCT's to assess more precisely and with higher statistical power the potential reduction of cardiac events by a systematic non-invasive CAD screening strategy in asymptomatic patients with diabetes mellitus.
Methods

Literature search
We performed a systematic search of medical articles published in peerreviewed journals from January 2000 to November 2017 in English, German, or French in five online literature databases (PubMed/MEDLINE, Cochrane Library, Embase, Scopus, and Web of Science) using the following words in titles, abstracts, or keywords: ('diabetes' or 'diabetic'), ('asymptomatic' or 'occult' or 'silent' or 'subclinical' or 'unknown'), ('coronary' or 'ischemia' or 'ischaemia' or 'CAD'), and ('screening' or 'detection' or 'diagnosis' or 'identification'). Additionally, we manually searched the bibliographies of relevant reviews and guidelines of the last 10 years.
Study selection
We selected publications according to the following criteria: (i) prospective RCT's published in peer-reviewed journals, (ii) patients with diabetes mellitus, without CAD symptoms or known CAD, (iii) randomisation to a non-invasive CAD screening strategy vs. standard care arm, and (iv) comparison of cardiac events after > _1 year of follow-up, analysed with the intention-to-treat principle. Non-RCT's with an adequate control group and meeting all other criteria were included in additional analyses. An overview of the search protocol is presented in Figure 1 .
Outcomes
Our primary endpoint 'any cardiac event' was a composite of cardiac death, non-fatal MI, unstable angina (UA), or heart failure (HF) hospitalisation. Secondary endpoints were the individual components of the primary endpoint, all-cause death, coronary revascularization (regardless of percutaneous vs. surgical, as part of the screening protocol or not), and medication use.
Data extraction
Two investigators (O.F.C. and O.G.) independently extracted data regarding trial characteristics, potential bias, and pre-specified cardiac outcomes from the selected RCT's using standardised forms designed for this study. Differences were solved by consensus. Composite outcome data were patient-based (i.e. one patient with several events counted as one positive case). For one study, 24 we re-included one patient excluded for early non-cardiac death. Moreover, we contacted the authors of all selected trials to complete our outcome data. Thus, we were able to include unpublished results in our analyses.
Study quality and risk of bias
The study quality assessment comprised the risk of study bias, the publication bias, and the overall quality of evidence. The risk of study bias was assessed at the study and outcome level using the Cochrane Collaboration's tool. 25 Publication bias was evaluated using funnel plots 26 and the Harbord-Egger test for asymmetry. 27, 28 Finally, overall quality of evidence was assessed using 31 We performed a metaanalysis of relative risks (RRs) with 95% confidence intervals (CIs) using the Mantel-Haenszel method and the fixed effect model. 32 A random effects model 33 was used if heterogeneity was significant (P < _ 0.10 or 31 and in all additional analyses including non-RCT's. The number needed to screen (NNS) was calculated for outcomes with significant results. All statistical tests were two-sided, and P-values <0.05 were considered as statistically significant, except <0.10 for heterogeneity analyses, as recommended. 31 
Sensitivity analyses
For all primary and secondary endpoints, we sequentially excluded each trial from the meta-analysis to assess its specific effect on the pooled RR and significance.
Additional analyses including nonrandomised trials
All primary and secondary endpoints were re-analysed after including data from the selected non-RCT's.
Regulatory aspects
Because our study did not directly involve patients, but only outcome data from other studies, no approval from the local ethics committee was required. However, all selected trials reported about approval by an institutional review board and informed consent by each patient. Our analysis complied with the Declaration of Helsinki. We presented our results according to the PRISMA statement about systematic reviews and metaanalyses. 34 This study did not receive any funding.
Results
Literature search
Our literature search covered five online databases (5392 total records), and was completed using 35 reviews (1737 references 36 Study characteristics Table 1 presents important characteristics of the selected RCT's. These trials included between 141 and 1123 patients, with a total of 3299 patients. Mean age ranged from 60.1 to 63.9 years, the proportion of male patients from 52% to 80% and mean follow-up duration from 3.5 to 4.8 years (weighted mean 4.1 years). Inclusion criteria were based on age and presence of diabetes, and three studies required additional cardiovascular risk factors. Screening was performed with EET, SE, MPI, CTCA with CACS, or a combination of them. The studies also vary in the type of clinical response with which pathological imaging findings were met: in DIAD, patients were treated according to the best judgment of the primary medical provider. In DYNAMIT, further investigations were left at the cardiologist's decision. In Faglia et al. 24 and DADDY-D, patients with positive tests were directly offered an invasive coronary angiography (ICA). FACTOR-64 provided protocol-based recommendations to the referring physicians on intensification of medical treatment and the use of ICA or further non-invasive testing based on the severity of findings. All selected RCT's consistently found non-significant reductions of cardiac events in the screening arm, except Faglia et al. 24 showing significant reductions of major and all cardiac events.
Study quality and risk of bias
The five RCT's had a globally low risk of study bias when assessed with the Cochrane tool (see Supplementary data online, Figure S1 ). Importantly, all of them seemed non-blinded to patients and physicians regarding trial arm. However, knowledge of screening status and screening results was an integral part of the interventions and Figure S2 ). However, we found no significant asymmetry with the Harbord-Egger test (P = 0.123 for the main composite outcome). Finally, the individual trials lacked precision, due to broad CIs, but performing a meta-analysis produced more precise results. However, these analyses are limited in the presence of five RCT's. Thus, we rated the strength of evidence as moderate, according to the updated GRADE method.
Primary outcome and its components
In our sample of five RCT's, a total of 3299 patients were randomised to a screening arm (n = 1652) or a control arm (n = 1647 Supplementary data online, Figure S3 ].
Sensitivity analysis
In the primary endpoint analysis, excluding Faglia et al. 24 
Additional analyses including nonrandomised trials
In the literature search, we found two relevant non-RCT's with appropriate control groups, both showing reductions in cardiovascular events in screened asymptomatic patients with diabetes: one by Gazzaruso et al. 37 using EET ± SE or MPI and one by Tsujimoto et al. 38 using MPI. Including these non-RCT's into the primary outcome analysis resulted in a stronger reduction of any cardiac event by 42% [RR 0.58 (95% CI 0.37-0.91), P = 0.017, I 2 = 66%, NNS = 35, Figure S4 .
Discussion
The present meta-analysis of five RCT's including 3299 asymptomatic diabetic patients compared a strategy of routine CAD screening vs. standard of care with regard to cardiac outcomes over a weighted mean follow-up of 4.1 years. We found a significant reduction in the primary composite endpoint of any cardiac event by 27%. This endpoint reduction was mainly driven by lower rates of non-fatal MI (-35%) and HF hospitalisations (-39%), although both findings fell short of statistical significance when assessed separately. Fifty-six asymptomatic Type 2 diabetics would have to undergo CAD screening to prevent one cardiac event over a 4-year follow-up. Overall Figure 2 Meta-analysis of the primary endpoint: any cardiac event.
Any cardiac event is a composite of cardiac death, non-fatal myocardial infarction, unstable angina, or heart failure hospitalisation. quality of evidence was high. Including data from two nonrandomised trials in the meta-analysis further strengthened the effect of screening on the primary endpoint (-42%) and even showed a significant reduction in non-fatal MI by 48% in favour of screening. This primary outcome reduction was fairly homogenous over the five trials included in the meta-analysis, but fell short of statistical significance when assessed separately in each individual trial (except in the small trial by Faglia et al. 24 ). This may be explained by a Type II statistical error, in which the null hypothesis fails to be rejected due to systematic under-sampling, caused by the unexpected low cardiac event rates in all trials. Indeed, in DIAD and FACTOR-64, the two largest RCT's included in this meta-analysis, the average annual major cardiac event rate (cardiac death or MI) was 0.6%, and 0.8%, respectively, i.e. 3-4 times lower than anticipated. 22, 23 Unlike the other RCT's, all of which had higher event rates, DIAD and FACTOR-64 did not require additional risk factors as inclusion criteria. Hence, it is likely that both trials were underpowered to detect small differences in risk at a reasonable power (80-90%). Most of the studies encountered difficulties in enrolling patients: DYNAMIT was stopped early due to low patient recruitment rates, 35 whereas FACTOR-64 and DADDY-D compensated low recruitment rates by extending the follow-up duration. 23, 36 The present meta-analysis overcomes the statistical limitations of the individual trials to some extent and confirms the small but significant tendency towards improved outcomes with the use of a CAD screening strategy.
Notably, pathological screening results were treated differently across the different trials. In DIAD and DYNAMIT, specific treatment decisions regarding intensification of medical treatment and/or referral to ICA were left at the discretion of the treating physician or the study cardiologist. 22, 35 In Faglia et al. 24 and DADDY-D, 36 patients with pathological test results were directly offered an ICA. Only FACTOR-64 provided standardised protocol-based recommendations for treatment escalation in the screening arm: these included lower-than-standard goals for cholesterol, HbA1c, and blood pressure. Patients with severe or moderate coronary stenoses on CTCA were sent for ICA or further non-invasive testing, respectively. However, despite more aggressive treatment in 70% of patients in the screening arm of FACTOR-64, differences in lipid levels, blood pressure, and HbA1c between both groups were very modest after treatment. Coronary angiography and revascularization rates were slightly higher in the screening arm compared with the standardof-care arm. Possibly as a result of this, a small non-significant trend towards improved outcomes was observed in the screening arm. 23 In DIAD, there were no significant differences with regard to medical treatment and the rate of revascularization between both groups. In fact, only 15% of patients with moderate to large perfusion defects underwent ICA, and numerically more patients with normal imaging findings than patients with perfusion defects were revascularized. Almost 80% of patients with moderate to large perfusion defects, and 96% of patients with small perfusion defects were denied a Figure 3 Meta-analysis of components of the primary endpoint.
CAD screening in diabetic patients Figure 4 Meta-analysis of secondary endpoints. 12 These discrepancies between individual and recommended treatment decisions may account to some extent for the lack of benefit in the screening arm of DIAD. 22 In DYNAMIT and DADDY-D, drug usage and revascularization rates were similar among both groups, but severity of ischaemia and respective revascularization rates are not reported. 35, 36 Current recommendations for CAD screening in asymptomatic diabetic patients are rather restrictive, based on the negative results of the aforementioned screening trials. Multimodality appropriate use criteria for CAD detection consider EET as 'appropriate' and imaging tests as 'maybe appropriate' in asymptomatic diabetic patients. 39 European and American cardiological societies do not recommend systematic screening of asymptomatic diabetic patients, but consider CACS as reasonable and mention that stress imaging may be considered. 40, 41 However, the American Diabetes Association clearly discourages routine CAD screening on the following grounds 6 : on one hand, diabetic patients should already be on aggressive primary prevention therapies regardless of the presence or absence of significant CAD, on the other hand, large randomised trials did not report any global advantage of revascularization over medical therapy in unselected Type 2 diabetic patients with stable CAD. 20, 21 The present meta-analysis argues against current recommendations and encourages further research into screening strategies for asymptomatic diabetic patients. Given the large global prevalence of diabetes mellitus and the considerable costs of current non-invasive CAD imaging tests, it would be premature to recommend routine CAD screening for every asymptomatic diabetic patient. Moreover, the present meta-analysis did not demonstrate any mortality benefit with a screening strategy. However, the benefit of a screening strategy in this study can be compared with the effect of statin use for primary prevention of coronary heart disease events (-27%, number needed to treat 78). 42 Further large and appropriately powered trials are required to allow a more precise analysis of the magnitude of benefit and to assess pre-specified subgroups in which screening strategies may offer larger benefits. Then, costeffectiveness studies should assess the financial impact and economic benefits of a CAD screening programme in diabetic patients.
Limitations
This meta-analysis was based on a variety of screening modalities: FACTOR-64 used CACS and CTCA, 23 while DIAD was conducted with MPI, 22 DYNAMIT and DADDY-D relied on EET, 35,36 whereas Faglia et al. 24 combined EET and SE. These methodological differences may be perceived as a limitation of our meta-analysis. However, with the exception of EET, all CAD imaging tests have demonstrated uniformly a very high sensitivity and specificity for detecting CAD. 40 Moreover, all non-invasive tests predict cardiac events based on the severity of their findings, also in patients with diabetes. 8, 11, 14, 15 Furthermore, the extent of disease has been shown to interact with the treatment strategy with regard to cardiac outcomes. Thus, patients with more severe or extensive CAD on non-invasive testing have better outcomes with revascularization, while in patients with lower CAD severity, medical therapy appears equivalent. 12, 43 The design of this study-level meta-analysis precludes assessing specific subgroups for their respective benefits of screening strategies.
Given the small prognostic benefit of a routine screening strategy, it may well be that larger benefits are observed in specific subgroups, such as the very high-risk diabetic patients (e.g. those in which medical therapy fails to reach therapeutic goals or with multiple risk factors), the elder diabetics (as suggested in DADDY-D 36 ), or those with a high level of physical activity. Moreover, only FACTOR-64 included 12% of patients with Type 1 diabetes. 23 This corresponds to 3% of our pooled sample, with 97% of patients having Type 2 diabetes. Thus, our results essentially apply to Type 2 diabetes. However, our meta-analysis also has strengths, such as the low risk of bias of the selected RCT's, the overall quality of evidence, the detailed outcome assessment, the addition of unpublished data, and the additional analyses with non-randomised trials.
Conclusion
The present systematic review and meta-analysis suggests a reduction of cardiac events with the use of a CAD screening strategy in asymptomatic diabetic patients. These results should encourage further research into this issue by design of larger, appropriately sized randomised trials to address the exact magnitude of the effect in specific subgroups.
